Sweden-based Orexo has commenced patient dosing in a Phase III study to evaluate Zubsolv, a sublingual formulation of buprenorphine and naloxone. (Source: Drug Development Technology)
Orexo starts patient dosing in Phase III study of opioid dependence drug
Call 1 (888) 460-6556 to speak with a counselor.
